Shots:
- Mochida Pharmaceutical has entered into a development and commercialization agreement with Qilu Pharmaceutical for a biosimilar of follitropin alfa in Japan
- As per the deal, Mochida will lead development to secure marketing approval in Japan, collaborating with Qilu for early launch, and strengthening its position in Japan’s biosimilar market
- Follitropin alfa is a recombinant FSH used for controlled ovarian stimulation in ART and for inducing ovulation in conditions such as PCOS
Ref: Mochida Pharmaceutical| Image: Mochida Pharmaceutical and Qilu| Press Release
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
